CELG—Correction to bottommost paragraph of #msg-119362355: In the AGN-TEVA deal, AGN is retaining an earnout on 50% of the US sales of generic Revilimid; the details are in an attachment to AGN’s 7/28/15 8-K filing (http://www.sec.gov/Archives/edgar/data/1578845/000119312515265082/d70177dex21.htm ).